# Investor Newsletter

Issue 10 2023

MicroPort®




# MicroPort® CRM Announces Launch of ULYS™ ICD and INVICTA™ Defibrillation Lead in Japan

MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France with Global Operations, is pleased to announce the launch of the ULYS™ Implantable Cardioverter Defibrillator (ICDs) and INVICTA™ defibrillation lead in Japan. Both devices are MRI conditional at 1.5T and 3T when implanted as a system.

Kengo Kusano M.D., Director, Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, the National Cerebral and Cardiovascular Center in Osaka, Japan, stated: "Protection against inappropriate shock and exceptional longevity are key elements for ICD patient well-being and safety. MicroPort® CRM's expertise in these areas perfectly meets the clinical needs of patients, and it is good that these products can complement the offer on the Japanese market of implantable defibrillators."

Noboru Shimizu, VP of MicroPort® CRM Japan, declared: "Approximately 6300 patients receive ICD implants each year in Japan. I am confident that ULYS™ and INVICTA™ will enable us to strengthen our presence in our market. They perfectly complement our range of CRM devices with cutting-edge technology that we make available to doctors and their patients, aiming to provide high-quality therapeutic solutions."

MicroPort


## MicroPort® SkyWalker™ Hip and Knee Arthroplasty Robot is approved in China

Recently, the SkyWalker™ Robotic-Assisted Surgical System (SkyWalker™ or SkyWalker™ Hip and Knee Arthroplasty Robot), developed by MicroPort® NaviBot™, an associated company of MicroPort® MedBot™, has been approved by the National Medical Products Administration (NMPA) of China.

Mr. Yu Liu, Executive Vice President and Chief Business Officer of MicroPort® MedBot™, explained that, "The approval of the SkyWalker™ Hip and Knee Arthroplasty Robot will expedite MicroPort® MedBot™'s efforts to enhance the availability of high-quality medical resources and standardize the implementation of orthopedic robot clinical applications. It reflects the company's belief to 'Make Surgery Easier, Safer and Less Invasive'".

# MicroPort® MedBot™'s Toumai® Robot Completes the World's First 5G Remote Laparoscopic Robotic Surgical Trial on the 'Roof of the World'

Recently, MicroPort® MedBot™, in collaboration with West China Hospital of Sichuan University (West China Hospital) and Tibet Autonomous Region Hospital, successfully completed the world's first 5G remote laparoscopic surgical trial on the Qinghai-Tibet Plateau. Toumai® becomes the world's first laparoscopic surgical robot to perform 5G remote surgery at an altitude exceeding 3600 meters on, what is often referred to as, the 'Roof of the World'.

Mr. Yu Liu, Executive Vice President and Chief Business Officer of MicroPort® MedBot™, stated that, "The hospital is located in a distinctive environment characterized by high altitude, low air pressure, low oxygen levels, and large diurnal temperature fluctuations. Surgeons conducting long-duration, high-intensity surgeries under these conditions can quickly experience fatigue. By utilizing remote surgeries through 5G communication technology, we provide experts with an extended reach of capabilities that address both environmental challenges, ensuring the safe accuracy and efficient completion of surgeries."

Professor Fengming Luo, from West China Hospital, emphasized the profound social and academic significance of conducting this trial on the Qinghai-Tibet Plateau. He explained that it enables health professionals to perform remote surgeries for emergency treatment during natural disasters or unforeseen events, improving efficiency and benefiting a broader populace. He added that, "In the future, we aspire to challenge even higher difficulties; performing 5G remote surgical trials at altitudes of 4000 meters or even 5000 meters."

President of MicroPort® MedBot™, Dr. Chao He stated that, "We are dedicated to contributing to the promotion and advancement of remote medical care by providing better treatment options for patients, enhancing the working experience for surgeons, and delivering improved medical services to society."



MicroPort

# Investor Newsletter

MicroPort®

For more information, please contact:

**Martin Sun**
Chief Financial Officer
MicroPort Scientific Corporation
**Tel:** (86)(21) 38954600
**Email:** ir@microport.com

**Leanne Li**
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
**Tel:** (86)(21) 38954600
**Email:** ir@microport.com